Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Crispr Therapeutics AG ( (CRSP) ) is now available.
On March 10, 2026, CRISPR Therapeutics AG announced plans to privately offer $350 million of convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $52.5 million. The notes will be senior unsecured obligations paying semiannual interest, maturing March 1, 2031, and convertible into the company’s common shares, with proceeds earmarked for general corporate purposes.
On March 11, 2026, the company disclosed that investor demand allowed it to upsize the planned convertible notes issuance to $550 million in aggregate principal amount. The successful pricing and expansion of the offering underscore CRISPR Therapeutics’ ability to tap capital markets to support its growing gene-editing franchise and may strengthen its financial flexibility as it advances commercial and pipeline programs in a competitive biotech landscape.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
Spark’s Take on CRSP Stock
According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.
The score is held down primarily by weak and volatile financial performance (episodic collaboration revenue, large losses, and ongoing cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Offsetting factors include a comparatively strong, low-leverage balance sheet and a positive pipeline/corporate update that supports longer-term potential, but valuation is not supported by profitability (negative P/E) and there is no dividend yield.
To see Spark’s full report on CRSP stock, click here.
More about Crispr Therapeutics AG
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing gene-based medicines for serious human diseases, having evolved from a research-stage pioneer into an industry leader. The company’s portfolio includes CASGEVY, the first approved CRISPR-based therapy for eligible sickle cell disease and transfusion-dependent beta thalassemia patients, and a diversified pipeline spanning hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases.
Headquartered in Zug, Switzerland, CRISPR Therapeutics operates R&D centers in Boston and San Francisco through its U.S. subsidiary, CRISPR Therapeutics, Inc., and is expanding its gene-editing leadership via its proprietary SyNTase platform. The company also leverages strategic collaborations with major partners, including Vertex Pharmaceuticals, to accelerate development and commercialization of its gene-editing therapies.
Average Trading Volume: 1,791,155
Technical Sentiment Signal: Sell
Current Market Cap: $5.07B
Learn more about CRSP stock on TipRanks’ Stock Analysis page.